首页> 外文期刊>Annals of surgical oncology >Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
【24h】

Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).

机译:Blueprint 80-基因功能亚型和Mammaprint预测的化学敏感性在预期的Neoadjuvant乳房注册表交响曲 - 交响曲试验(NBRST)中。

获取原文
获取原文并翻译 | 示例
           

摘要

BluePrint molecular subtyping reclassifies 22 % (94/426) of tumors, reassigning more responsive patients to the HER2 and Basal categories while reassigning less responsive patients to the Luminal category. These findings suggest that compared with IHC/FISH, BluePrint more accurately identifies patients likely to respond (or not respond) to NCT.
机译:蓝图分子亚型重新分类22%(94/426)肿瘤,将更响应的患者重新分配给HER2和基础类别,同时重新分配对腔类别的较少响应患者。 这些研究结果表明,与IHC / FISH相比,蓝图更准确地识别可能对NCT响应(或不响应)的患者。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号